Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -685.57%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-594.91%
RETURN ON EQUITY (ROE) AVG 3Y
-391.26%
RETURN ON EQUITY (ROE) AVG 5Y
-191.38%
RETURN ON EQUITY (ROE) AVG 10Y
-133.35%
RETURN ON EQUITY (ROE) AVG 15Y
-189.37%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GlucoTrack, Inc.
Market Cap
$885859.00
Return on Equity (ROE)
N/A
TTM Avg
-594.91%
3Y Avg
-391.26%
5Y Avg
-191.38%
Market Cap
$880215.00
Return on Equity (ROE)
-21.18%
TTM Avg
-23.90%
3Y Avg
-48.17%
5Y Avg
-962.79%
Market Cap
$859931.00
Return on Equity (ROE)
-73.66%
TTM Avg
-87.93%
3Y Avg
-127.18%
5Y Avg
-86.65%
Market Cap
$853968.00
Return on Equity (ROE)
-334.41%
TTM Avg
-290.71%
3Y Avg
-280.75%
5Y Avg
-198.19%
Market Cap
$824357.00
Return on Equity (ROE)
-77.23%
TTM Avg
-124.66%
3Y Avg
-168.43%
5Y Avg
-110.88%
Market Cap
$791587.00
Return on Equity (ROE)
N/A
TTM Avg
15.66%
3Y Avg
-28.27%
5Y Avg
-26.31%
Market Cap
$1.03M
Return on Equity (ROE)
-93.97%
TTM Avg
234.49%
3Y Avg
123.23%
5Y Avg
1171.22%
Market Cap
$1.08M
Return on Equity (ROE)
-57.87%
TTM Avg
-222.45%
3Y Avg
-164.72%
5Y Avg
-135.78%
Market Cap
$675543.00
Return on Equity (ROE)
6.58%
TTM Avg
129.48%
3Y Avg
106.12%
5Y Avg
-3462.32%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GlucoTrack, Inc. (GCTK) | $885859.00 | N/A | -594.91% | -391.26% | -191.38% |
| Sunshine Biopharma, Inc. (SBFM)vs › | $880215.00 | -21.18% | -23.90% | -48.17% | -962.79% |
| Bone Biologics Corporation (BBLG)vs › | $859931.00 | -73.66% | -87.93% | -127.18% | -86.65% |
| Decoy Therapeutics Inc. (DCOY)vs › | $853968.00 | -334.41% | -290.71% | -280.75% | -198.19% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $824357.00 | -77.23% | -124.66% | -168.43% | -110.88% |
| Ridgetech, Inc. (RDGT)vs › | $791587.00 | N/A | 15.66% | -28.27% | -26.31% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | -93.97% | 234.49% | 123.23% | 1171.22% |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | -57.87% | -222.45% | -164.72% | -135.78% |
| CDT Equity Inc. (CDT)vs › | $675543.00 | 6.58% | 129.48% | 106.12% | -3462.32% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | -11.85% | -6.20% | 47.36% | 47.36% |
ROE
N/A
ROA
-1066.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -685.57% |
| 2025-09-30 | -939.80% |
| 2025-06-30 | -389.10% |
| 2025-03-31 | -365.16% |
| 2023-12-31 | -221.99% |
| 2023-09-30 | -107.47% |
| 2023-06-30 | -60.40% |
| 2022-12-31 | -360.57% |
| 2022-09-30 | -197.62% |
| 2022-06-30 | -142.01% |
| 2022-03-31 | -100.59% |
| 2021-12-31 | -78.89% |
| 2021-09-30 | -52.92% |
| 2021-06-30 | -43.17% |
| 2021-03-31 | -35.17% |
| 2020-12-31 | -30.02% |
| 2020-09-30 | -24.29% |
| 2020-06-30 | -27.86% |
| 2020-03-31 | -29.66% |
| 2012-03-31 | -590.77% |
| 2011-12-31 | -244.19% |
